Amarin reported $49.22M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 17.4B 410M Sep/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Amarin USD 49.22M 451K Dec/2025
AstraZeneca USD 16.21B 830M Sep/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
DBV Technologies USD 1.6M 955K Sep/2026
GlaxoSmithKline GBP 8.89B 480M Sep/2026
Halozyme Therapeutics USD 492.97M 11.97M Sep/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Ionis Pharmaceuticals USD 243M 25M Sep/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 1.12B 161M Sep/2026
Novartis USD 14.52B 112M Sep/2026